ClinicalTrials.gg
RecruitingNCT06901245Updated Sep 16, 2025

Tirzepatide in PWS, HO and GNSO

A Phase 4 interventional study of Tirzepatide in Prader-Willi Syndrome, Hypothalamic Obesity and Obesity/Therapy, sponsored by Grace Kim. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 26 Years. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Grace Kim · Phase 4, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 26 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.

Planned enrollment
22nd of 58
36 · median 23
Started
2025
with 4 others
Phase 4
3 of 69
1 open now
Primary completion
2026-06
later than 0 of 13 live
Registered
64th of 69
by date

Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 22nd largest by planned enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 4, reaches primary completion later than 0 of the 13 other live ones, and was the 64th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 26 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Prader-Willi Syndrome with a site in United States, or all of them as a file.
02

Study summary

This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.

Read the detailed description

This study is for the following individuals:

  • Age 18-26.
  • Have Prader-Willi Syndrome, Hypothalamic Obesity, or Obesity unrelated to a genetic syndrome or medical condition.
  • Have a BMI in the obesity range

If you/your child decide to take part in the research study, you/your child would participate in the study for approximately 56-60 weeks. During this time the following can be expected:

  • Receive tirzepatide for once-weekly dosing.
  • Complete 6 in-person SCH study visits
  • Complete 4 telehealth visits.
  • Complete the following research procedures:

    • Medical Record Review
    • Vital Signs
    • Anthropometry (e.g., height, weight, waist measurements)
    • Physical Exams
    • Laboratory Tests (e.g., fasting blood draws, urine test)
    • Dual-Energy Absorptiometry (DXA) scans
    • Questionnaires
03

Conditions studied

  • Prader-Willi Syndrome
  • Hypothalamic Obesity
  • Obesity/Therapy

Keywords

  • Tirzepatide
  • GLP1 Agonist
  • Obesity
  • Prader-Willi Syndrome
  • Hypothalamic Obesity
  • General Obesity
04

Who can participate

Ages eligible
18 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals 18-26 years with a in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) with either 1) genetically confirmed diagnosis of PWS, 2) hypothalamic obesity as defined by damage to the medial hypothalamic region resulting in dysregulation of satiety and energy balance as diagnosed by a physician, 3) general obesity unrelated to a genetic syndrome or underlying medical condition
  • In a stable care setting at least 6 months prior to enrollment
  • Able and willing to participate in study visits including tolerating blood draws, urine samples and tolerate DXA scan.
  • Ability to take weekly subcutaneous tirzepatide
  • Consistent caregiver if they are not independent
  • Stable diet and exercise regimen for at least 6 months prior to enrollment
  • Able to use methods if able to conceive offspring in order to prevent unintentional pregnancy during the study

Exclusion criteria

Exclusion Criteria:

  • Current or recent (within 3 months of start of study drug initiation) use of weight loss medications
  • Current use of insulin or sulfonylurea or other medication affecting insulin secretion or GLP1 clearance
  • Current or prior use of any GLP1A or DPP4 inhibitor during the 6 months before screening
  • Any medications that may affect the study endpoints
  • Significant weight change (>3% weight gain or loss) in the last 2 months prior to enrollment
  • Change in dose of chronic endocrine medications (testosterone, estrogen, levothyroxine, or growth hormone medications) >10%/kg/day for at least 3 months prior to study
  • Current pregnancy or desire to become pregnant within study period, current lactation
  • History of recurrent pancreatitis, CKD, gastroparesis
  • Chronic/acute heart, kidney, or liver disease
  • Personal or family history of medullary thyroid carcinoma or MEN syndrome type 2
  • Uncontrolled diabetes ( >8.5%)
  • DVT
  • Cancer within the previous 5 years
  • Current participation in an interventional clinical study
  • Previous or planned surgical treatment for obesity
  • Individuals with current substance abuse equivalnt to moderate or severe based on DSM 5 criteria (Hasin DS, 2013)
  • Any suicidal ideation in the past year
  • Unable to perform any of the procedures for the study
  • Have a body weight, height, and/or width that that prohibits the ability to obtain accurate measurements according to the DXA manufacturer's specification
  • Any condition that would prevent successful participation in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Active comparator
    Prader-Willi Syndrome

    Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) with genetically confirmed Prader-Willi Syndrome between 18-26 years old.

    Drug: Tirzepatide

  • Active comparator
    Hypothalamic Obesity

    Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) and hypothalamic obesity as defined by damage to the medial hypothalamic region resulting in dysregulation of satiety and energy balance as diagnosed by a physician.

    Drug: Tirzepatide

  • Active comparator
    General Non-Syndromic Obesity

    Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) and general obesity unrelated to a genetic syndrome or underlying medical condition.

    Drug: Tirzepatide

Interventions

  • Subjects will take Tirzepatide for 48 weeks

06

What researchers measure

Primary outcomes

  1. Change in weight

    Weight will be measured in kilograms through anthropometric measurements. Change in percent weight from baseline to week 48 of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity will then be assessed.

    Time frame: 48 weeks

Secondary outcomes

  1. Change in BMI

    Change in BMI from baseline to 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity through anthropometric measurements. BMI will be calculated using weight (kg) and height (m) which will be combined to report BMI in kg/m\^2. The percent change in this BMI value from baseline to 48 weeks will be calculated.

    Time frame: 48 weeks

  2. Change in fat mass

    Change in fat mass (measured in kg by DXA scan) from baseline to 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity.

    Time frame: 48 weeks

  3. Change in appetite - CoEQ (Control of Eating Questionnaire)

    Change in appetite during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity using an appetite questionnaire (CoEQ - Control of Eating Questionnaire). CoEQ is a 21-item scale to assess the severity and type of food cravings an individual experiences using a visual analog scale. Higher scores indicate higher severity of hyperphagia.

    Time frame: 48 weeks

  4. Change in appetite - Physician Rated Hyperphagia Severity Scale

    Change in appetite during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity assed with a physician rated hyperphagia severity scale. This is a 5 point scale (0 to 5) to rate clinical imppression of hyperphagia severity. Higher scores mean more severity.

    Time frame: 48 weeks

  5. Change in metabolic markers - fasting lipids

    Change in metabolic markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: fasting lipids via lipid profile assay via blood sample

    Time frame: 48 weeks

  6. Change in metabolic markers - fasting plasma glucose

    Change in metabolic markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: fasting plasma glucose, via chemistry panel via blood sample

    Time frame: 48 weeks

  7. Change in metabolic markers- fasting insulin

    Change in metabolic markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: fasting insulin via insulin assay via blood sample

    Time frame: 48 weeks

  8. Change in metabolic markers - hemoglobin A1C

    Change in metabolic markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: hemoglobin A1C via hemoglobin A1C assay via blood sample

    Time frame: 48 weeks

  9. Change in metabolic markers- Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

    Change in metabolic markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). This is product measuring insulin resistance calculated using fasting insulin and fasting glucose values. Higher numbers indicate more insulins resistance.

    Time frame: 48 weeks

Other outcomes

  1. Change in safety markers -CBC

    Change in safety markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: Complete Blood Count (CBC). This will be done with standard CBC assays via blood sample

    Time frame: 48 weeks

  2. Change in safety markers - CMP

    Change in safety markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: Comprehensive Metabolic Panel (CMP). This will be done with standard CMP assays via blood sample.

    Time frame: 48 weeks

  3. Change in safety markers - coagulation factor assay PT [prothrombin time]

    Change in safety markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: PT \[prothrombin time\], This assay will be done on drawn blood samples.

    Time frame: 48 weeks

  4. Change in safety markers - coagulation factor assay- PTT [Activated Partial Thromboplastin Time ]

    Change in safety markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: , PTT \[Activated Partial Thromboplastin Time \].This assay will be done on drawn blood samples.

    Time frame: 48 weeks

  5. Change in safety markers - coagulation factor assay - INR [international normalized ratio].

    Change in safety markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: INR \[international normalized ratio\]. This assay will be done on drawn blood samples.

    Time frame: 48 weeks

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jun 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
Mar 28, 2025
StartActual
May 1, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06901245
Lead sponsor
Grace Kim
Collaborators
Vanderbilt University Medical Center, Children's Hospitals and Clinics of Minnesota, Seattle Children's Hospital
Responsible party
Grace Kim (Principal Investigator, Seattle Children's Hospital) — Sponsor-investigator
First posted
Mar 28, 2025
Start date
May 1, 2025
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion